Although clinicians are not very satisfied with the accessibility and accuracy of PD-L1 expression and tumor-infiltrating immune cells in predicting the efficacy of PD-1/PD-L1 inhibitors, there is still a lack of convenient and reliable peripheral blood-derived markers to predict the efficacy and safety of immunotherapy. This evidence concerns the gene PDCD1 and neoplasm.